Get the Stockscreener App
10.37
3.29%
0.33
After Hours:
10.35
-0.02
-0.19%
Alpha Tau Medical Ltd stock is traded at $10.37, with a volume of 795.90K.
It is up +3.29% in the last 24 hours and up +28.18% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$10.04
Open:
$10.2
24h Volume:
795.90K
Relative Volume:
1.59
Market Cap:
$936.68M
Revenue:
-
Net Income/Loss:
$-42.63M
P/E Ratio:
-19.64
EPS:
-0.5281
Net Cash Flow:
$-39.43M
1W Performance:
-2.90%
1M Performance:
+28.18%
6M Performance:
+177.27%
1Y Performance:
+245.67%
1-Day Range:
$9.925
$10.71
1-Week Range:
$9.76
$11.62
52-Week Range:
$2.81
$11.62
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
10.37 | 906.87M | 0 | -42.63M | -39.43M | -0.5281 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
DRTS Technical Analysis | Trend, Signals & Chart Patterns | ALPHA TAU MEDICAL LTD (NASDAQ:DRTS) - ChartMill
Alpha Tau Medical stock surges as interim brain tumor trial data sparks rally - MSN
Alpha Tau Medical shares early Regain data: 2 complete responses in glioblastoma study - MSN
H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target - Investing.com India
H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target By Investing.com - Investing.com Australia
DRTSW Stock Price, Quote & Chart | ALPHA TAU MEDICAL LTD -27 (NASDAQ:DRTSW) - ChartMill
Piper Sandler raises Alpha Tau Medical stock price target on milestones - Investing.com Nigeria
Alpha Tau Medical Releases Q1 2026 Financial Results - AlphaStreet
Alpha Tau price target raised to $8 from $5 at Piper Sandler - TipRanks
Japan Approves Alpha DaRT, a Breakthrough in Cancer Radiation Therapy - BriefGlance
Piper Sandler raises Alpha Tau Medical stock price target on milestones By Investing.com - Investing.com South Africa
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - Sahm
Alpha Tau Medical stock (IL0011833879): Q1 trial progress and investor conferences lift focus - AD HOC NEWS
Alpha Tau Medical earnings missed by $0.14, revenue fell short of estimates - Investing.com Australia
Alpha Tau Medical Sets June 23, 2026 Shareholder Meeting to Vote on Governance and Executive Pay - TipRanks
Alpha Tau Medical Posts Strong Q1 2026 Trial Progress and Completes Enrollment in First U.S. Pivotal Study - TipRanks
Alpha Tau Medical (NASDAQ: DRTS) sets 2026 shareholder vote on pay, board and auditors - Stock Titan
Alpha Tau Medical Ltd options imply 16.0% move in share price post-earnings - TipRanks
Alpha Tau (NASDAQ: DRTS) posts larger Q1 2026 loss while cancer trials reach key milestones - Stock Titan
Press Release: Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Alpha Tau to Participate in May Investor Conferences - GlobeNewswire
DRTS Q1'26 Earnings: revenue estimate is 49.75K USD - TradingView
NASDAQ New 52-Week Highs And Lows - Moomoo
Alpha Tau Medical (DRTS) price target increased by 13.16% to 10.96 - MSN
symbol__ Stock Quote Price and Forecast - CNN
Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
TradingKey - TradingKey
Ladenburg Thalmann Initiates Alpha Tau Medical(DRTS.US) With Buy Rating, Announces Target Price $14 - Moomoo
H.C. Wainwright raises Alpha Tau Medical stock price target to $15 on trial data - Investing.com UK
H.C. Wainwright raises Alpha Tau Medical stock price target to $15 on trial data By Investing.com - Investing.com South Africa
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally - Sahm
Alpha Tau Says Complete Response in 2 Brain Cancer Patients Observed in Interim Trial of Radiation Treatment - Moomoo
Alpha Tau Medical Shares Gain on Positive Results From Brain-Cancer Treatment Trial - Moomoo
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Alpha Tau Medical (NASDAQ:DRTS) Sets New 52-Week HighTime to Buy? - MarketBeat
Alpha Tau Wiped Out Visible Tumors in Two of Three Brain Cancer Patients in Its First U.S. Trial - TipRanks
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study - MarketBeat
Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT - TipRanks
Alpha Tau (DRTS) shows early Alpha DaRT results in recurrent GBM trial - Stock Titan
Alpha Tau reports interim results from brain cancer trial By Investing.com - Investing.com Australia
Alpha Tau Medical stock surges on brain cancer trial results By Investing.com - Investing.com Nigeria
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):